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1. Introduction
Tuberculosis (TB) has traditionally been one of the major causes of pleural disease and until
the earlier decades of the past century held as a principal paradigm of “pleuritis”. Indeed in
the presence of a distinctly exudative effusion and a compatible clinical presentation the widely
used term “pleuritis exudativa” insinuated a tuberculous aetiology and has therefore been
understood to be synonymous with “pleuritis exudativa tuberculosa”. Whilst in the era of TB
decline in the Western hemisphere the term “pleuritis exudativa” (which actually is a tautol‐
ogy!) has largely survived but should now describe exudative effusions in general, the full and
precise term “pleuritis exudativa tuberculosa” is therefore suggested whenever the possibility
of a tuberculous background is addressed. Otherwise the term “tuberculous pleurisy” or
“tuberculous pleuritis” is used to describe this entity, in some countries also the term “specific
pleurisy” is common. Apart from acute pleuritis exudative tuberculosa, TB of the pleura may
however rarely present as a rather chronic disease state in terms of caseous pleurisy or specific
(i. e. tuberculous) empyema, respectively. The following chapter reviews the different features
and mechanisms of tuberculous pleural involvement as well as their diagnostic and thera‐
peutic implications.
2. Epidemiology
In many regions of the world tuberculous effusion maintains its role as the leading inflam‐
matory pleural disease. With the worldwide unabated HIV epidemic and related immune
deficiency syndrome this state of affairs is likely to continue or being even aggravated within
least in certain high risk populations. On a global scale the current significance of human
immunodeficiency virus (HIV)-co-infection may be illustrated by WHO data, indicating at a
TB-prevalence of 1/3 of the world´s population – similar to the past decade – a HIV-association
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of approximately 13 % by the year 2009 [1, 2]. Conversely it is assumed, that 33 % to 50 % of
HIV infected individuals are co-infected with M. tuberculosis [2]. The MTB/HIV-association
however shows a huge intercontinental and regional variance, with the highest rate of HIV-
pleural tuberculosis-coincidence being reported in Zimbabwe where 95 % of Patients with
tuberculosis pleurisy were HIV positive [3]. In Burundi and Tansania a HIV-coinfection was
found in 60 % of all cases of tuberculous pleurisy [4]. One of the lowest rates is reported from
Spain with 10 % [5]. Am example of the impact of a high HIV-endemic environment on the
incidence of tuberculous pleurisy is also given in a series from Ruanda, where TB accounted
for as much as 86 % of all diagnosed pleural effusions [4]. Pleurisy incidence obviously and
essentially parallels variability of global TB prevalence with an overwhelming share of 95 %
occurring in developing countries. In TB-patients as a whole, pleural involvement varies
between ~ 3-5 % in Western Europe and the USA vs. ~ 30 % in developing, HIV-high-preva‐
lence-countries [6, 7, 8]. The differences clearly underline the modifying role of immunological
determinants, stage and severity of the disease, general health status and nutritional factors.
The effect of HIV on the occurrence of pleural involvement in a given TB-patient is illustrated
by a study reporting a 38 % pleurisy incidence in AIDS-associated TB as compared with 20 %
in matched HIV-negative TB patients [5]. On the basis of the presented data according to even
conservative WHO estimates the TB-pleurisy incidence throughout the current decade is
expected to remain grossly unchanged compared to the past decade, i. e. 18.2 – 62/100.000 in
the developing countries vs. 0.42-0.77/100.000 in Western countries [6, 7, 10]. When the
epidemiology of pleurisy (or pleural effusion in general) is analysed in terms of the magnitude
of TB-contribution, a probably still valid estimate in Western countries is as low as 0.1 – 0.2 %
and remains distinctly < 1 % even when referring to pleurisy in a strict sense (i. e. exudates)
[11]. By comparison the previously reported percentages of 30-86 % in developing countries
are – and remain – indeed dramatically different.
3. Pathophysiology and natural history
3.1. Immunological and microbiological factors
MTB may affect the pleura at different stages of pulmonary or systemic disease and by a
number of different mechanisms. Thus pleural involvement occurs in primary, postprimary
and reactivated TB alike and is basically believed to arise directly from contiguous macroscopic
or microscopic lung lesions or else lymphogenic or hematogenic spread, but probably also via
immunogenic mechanisms. Pleuritis exudativa tuberculosa is by far the most common clinical
variety and has been classically interpreted as an early delayed-hypersensitivity-type phe‐
nomenon rather than direct organ involvement [12, 13]. Many clinical observations and
experimental findings are in favour of this hypothesis such as:
• its frequent association with known primary infection and a typical 6-12 weeks latency,
• an often striking absence of significant pulmonary or systemic TB-lesions,
• an often culturally negative or paucibacillary effusion [14],
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• the sometimes abundant isolation of specifically purified protein derivative (PPD)- protein
sensitized T-lymphocytes from pleural fluid [15] and
• more recently the inducible pleurisy in previously PPD-sensitized animals when exposed
to intra-pleural mycobacterial protein.
Also the vigorous expression of inflammatory mediators interleukins (IL) like interferon (IFN)
γ, IL-1 and IL-8 observed in this model (or conversely their suppression by antilymphocyte
serum) support this view [16, 17].
On the other hand there is also strong evidence, that infectious invasion of the pleural space
actually occurs at a substantial, albeit variable degree. At thoracoscopy, even with negative
fluids studies, extensive inflammatory granuloma formation and fibrin deposits with unex‐
pected abundant mycobacteria recovery are a common finding (see also section on invasive
endoscopic-bioptic studies) [18]. The increasingly emerging evidence of a preferred association
of TB-pleurisy with reactivated TB in Western populations clearly points to infectious as well
as immunological mechanisms being interrelated and operative in a complex manner. Direct
infectious invasion however clearly prevails in chronic tuberculous involvement of the pleura
as in specific empyema.
According to present views and based on experimental evidence the sequence of immunologi‐
cal processes involved in TB-pleuritis appears to follow a three stage pattern of cellular reactions
and granuloma formation as a topic variant of general interaction mechanisms between MTB
and the human immune system. A schematic representation is given in figure 1 [19, 20].
Any trigger-mechanism that allows access of mycobacterial protein to the pleura will set off a
rapid mesothelial cell initiated and IL-8 mediated polymorphonuclear neutrophil (PMN)
influx within a few hours [21]. In addition macrophages and blood-borne monocytes deter‐
mine this IL-1, IL-6 and tumor necrosis factor (TNF)-α-orchestrated early stage reaction.
Within roughly 3 days, in the following intermediate stage lymphocyte subpopulations, mainly
of CD4+ helper cells but also a substantial CD8+ cytotoxic (natural killer cells) fraction
dominate the scene resulting in a CD4+/CD8+-ratio of ~ 4.3 [22]. A minor contribution includes
so-called T-cell receptor double negative (DN) αβ-T-cells and γδ-T-cells which appear to have
regulatory functions. More recently in tuberculous pleural fluid another unique CD4+CD25+
T-cell-class could be demonstrated being specifically involved in the down-regulation of auto-
reactive IFN-γ-producing T-cells, thus preventing inflammatory overshoot [23]. IFN-γ a strong
promoter of macrophage activation and granuloma formation (together with TNF-α) is the
predominant interleukin in this stage. IFN-γ-producing cells have been phenotypically
indentified as CDW29+ subpopulation and make up a substantial portion of the granuloma
core structure [24].
The  late  phase  is  characterised  by  an  equilibrated  and  sustained  CD4+/CD8+  cell-based
response  with  continued  IFN-γ  release  and  prolonged  granuloma  formation.  Several
modulating interleukins are involved in this process such as T-helper-cells (CD4+)-support‐
ing IL-12 and counter-regulatory antiinflammarory cytokines like IL-10 and transforming
growth factor (TGF-β).
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Results of HIV and AIDS research also emphasize the importance of T-cell response. Several
working groups have shown, that the prevalence of tuberculous pleurisy in HIV-infected patients
with TB is strikingly correlated with their CD4+ blood lymphocyte count. In one series pleuri‐
sy prevalence in individuals with a count of > 200 cells/ml was 27 % as compared to 10 % in those
with a count of < 200 cells/ml [25]. The data support the view, that the clinical expression of
exudative pleural effusion requires a largely intact cellular immune system and features pleurisy
as a high activity response in a still immunocompetent individual. In epidemiologic terms one
would conclude that pleural effusion should be more frequent in the still immunocompetent
host than in patients with AIDS. In reality however in most HIV-high-prevalence countries like
South Africa, Uganda and Zimbabwe the percentage of thoracic TB-patients with pleural effusion
is reportedly higher in HIV+ patients [26]. As an explanation the situation is probably blurred
by a variable and poorly defined immune status in HIV+ individuals.
Figure 1. Mechanisms and immunogenesis of tuberculous pleurisy: the three stages of protective immune response.
IFN: interferon; TNF: tumor necrosis factor; IL: interleukin; PMN: polymorphonuclear granulocyte; X: undefined cell;
MΦ: macrophage, MTB: mycobacterium tuberculosis; PPD purified protein derivative
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3.2. Other factors
The mechanisms of fluid accumulation and of abundant protein leakage to the pleura with
often extensive fibrin deposits in tuberculous pleurisy have so far not been fully elucidated.
In actual fact pleuritis exudativa tuberculosa generally presents with the highest protein levels
commonly seen in exudative conditions. The intensity of inflammation and a proportionately
increased vascular permeability would provide a satisfying explanation [25, 27] although at
least in animal models, no such significantly altered vascular permeability could be demon‐
strated [12]. Current opinion holds that grossly impeded lymphatic protein clearance from the
pleura due to altered parietal lymphatic channels is probably of tantamount importance.
Again the entry mechanism of mycobacteria to the pleura has remained unclear. It is usually
assumed that the release of infectious material from a ruptured subpleural TB-lesion is the
most common mechanism. While this is likely to occur in more or less extensive pulmonary
TB, it would not explain the frequent association of tuberculous pleuritis with an – at least
radiographically – unaffected lung. There are also no convincing data yet to quantify the
contribution of a purported hematogenous or lymphogenous contribution. One might
reasonably speculate that different patterns of pleural tuberculous involvement are operative
which might correspond to the different clinical settings of primary, post-primary and
reactivated TB.
Caseous tuberculous pleuritis or specific empyema is nowadays a rare condition which is believed
to be the result of longstanding or chronic infection of the pleura, when either caseous material
gains access to the pleura or chronic pleuritis develops on the background of impaired local
defence such as pre-existing fibrous damage of the pleura or as a sequel and complication of
artificial pneumothorax, oleothorax or other TB-specific surgery dating back to the pre-
chemotherapy era. Correspondingly there is usually an extremely long history often with a
remarkable paucity or even absence of symptoms. Penetration to deeper chest wall structures
(specific abscess) and ultimately transcutaneous discharge (empyema necessitans) or creation
of a specific bronchopleural fistula, as not infrequently seen in the pre-chemotherapeutic era,
may complicate this condition [27]. Putrid discharge from a thoracic mass or putrid expecto‐
ration with or without haemoptysis may ultimately advert to the condition.
4. Clinical manifestations and natural course
Tuberculous pleurisy may occur as an acute, subacute or rather chronic disease. At times the
course is also surprisingly oligosymtomatic. Therefore duration of symptoms or major illness
prior to hospital admission and diagnosis varies considerably from < 1 week (31 %) to < 1months
(62 %) or even longer (7 %) [28]. These data refer to the pre-HIV era and would not apply for HIV-
seropositive patients and elderly populations, which both tend to have a particularly long
symptomatic or else oligosymtomatic period. An infectious, i. e. febrile illness is nevertheless by
far the most common clinical presentation. As a general rule, an acute febrile illness is the more
likely to occur the younger and the more immunocompetent a given patient is. In developing,
high-prevalence and high primary-TB-affected countries the age peak of incidence is in the mid
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thirties, whereas in industrialized countries with a major contribution of reactivated TB it has
shifted to about 50 yrs [29]. But still the age-related incidence peak of tuberculous pleuritis is
distinctly lower than of parenchymal pulmonary TB which used to peak around 55 yrs [30].
Implicitly by the same statement in Western populations TB-pleurisy was historically more
symptomatic than is currently the case. In a representative series from the 1960-1970s ~ 60 % of
patients developed an acute illness mimicking bacterial (pleuro)-pneumonia with cough (70 %),
chest pain (75 %) and low- to high-grade fever (86 %) as the most frequent symptoms [31, 32].
Other symptoms include those commonly occurring in various TB disease states such as weight
loss, malaise and night sweat. Severe or even live threatening disease, defined as persistent high-
grade fever > 38,3°C over > 2 weeks or respiratory distress has been in reported in a more recent
series in only 7 % [31], whereas an oligosymptomatic or a febrile course is described in 14-33 %
[32]. Tuberculous pleurisy usually involves one hemithorax only (90-95 %) and is of limited size
(roughly up to one-half of the hemithorax volume). In a major series (n=254) effusions occupy‐
ing more than 2/3 of a hemithorax were noted in only 18 % [33]. Rarely effusion will occupy the
entire hemithorax and will almost never reveal compressive or displacing features [31]. Basically
there are no specific clinical clues to tuberculous etiology in pleurisy unless some TB-contact is
revealed or suspected. An HIV-related background may be suspected in a compatible clinical
and history setting or when there is a long preclinical period, unusual additional symptoms like
diarrhea and more hepato(spleno)-megaly or lymphadenopathy as might be attributed to the
tuberculous condition. Untreated, lone pleuritis exudativa tuberculosa in the short term seems
to be a self-limited inflammatory process in most instances, terminating in complete or incom‐
plete resolution within weeks or month. Frequently observed otherwise unexplained diaphrag‐
matic adhesions may be a late sequel of clinical silent or oligosymtomatic TB pleurisy. Importantly
however progression or reactivation to active pleuropulmonary or extrapulmonary TB occurs
in an important fraction. In one follow-up study the recurrence rate within 1 year was 5 %, where
TB did not relapse earlier than 8 month after the onset of pleurisy. Within a 4-5 yr period however
the rate was dramatically higher and in initially culture positive and culture negative subjects
with 65 % and 60 % respectively roughly alike [27]. One major outcome determinant clearly is
the presence and the extent of pulmonary involvement. At a similar therapeutic intensity in a
very recent major clinical study from Taiwan, 51 (24,9 %) out of 205 hospitalised patients having
been identified to have isolated (lone) pleuritis had a significantly better outcome, shorter hospital
stay and less comorbidity than the patients with pleuropulmonary disease [34].
5. Diagnosis
5.1. Clinical findings
5.1.1. Signs at physical examination
Physical examination clearly will provide only non-specific signs of pleural effusion in general
including dullness to percussion and the occasional demonstration of a pleural rub at auscul‐
tation (“snow-ball-crunching sign”) in particular in the presence of chest pain. Signs of a
trapped or loculated rather than free flowing fluid collection may suggest a tuberculous
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aetiology, but this observation holds also true for “plain” parapneumonic pleurisy. Usual signs
of systemic infection, as mentioned above, that should be looked for, may alert to the possibility
of a HIV-related background.
5.1.2. Imaging studies
Imaging techniques are engaged in the evaluation of tuberculous pleurisy following general
diagnostic pathway recommendations for effusion. Conventional chest radiography (CRX) requires
fluid amounts of at least 150 ml to become clearly detectable as blunting of the costodiaphrag‐
matic angle in standard projections. Profuse effusion with opacification of an entire hemithor‐
ax would rather favour differential diagnoses like malignancy in the elderly and afebrile patient
[35]. Free flowing effusion may be easily identified, but one should look specifically for signs of
loculation, pleural thickening or adhesions and in profuse effusion for compressive signs
interfering with the respiratory performance. Apart from pleural changes pulmonary infil‐
trates, nodules, lymphnodes and other suggestive signs of TB like encapsulated or cavitary
lesions must be carefully looked for using routine CT-imaging. CT-based prevalence of lung
perenchymal tuberculous lesions in mixed populations appears to be significantly higher than
previously assessed based on conventional radiography. In one recent series from Korea
comprising 106 patients with an age distribution from 16-89 yrs (mean 53) with 86% a remarka‐
ble high rate of parenchymal changes was found, presumed to represent active tuberculosis in
59 % [36]. Most of these lesions revealed features of reactivated rather than primary tuberculo‐
sis. Sonography (Ultrasound, US) using innovative technical achievements like high frequency
(5-7.5 MHz) – US and convex or sector scanners allow extended exploration of the chest wall
structures, the diaphragm and the anterior mediastinum up to a penetration depth of ~ 25 cm.
Specific advantages of US are a more precise fluid volumetry than by CRX, precise localisation
of septae, membranes and chambers as well as pleural thickening along with its particular
versatility for bedside diagnosis. On demand guidance for interventions such as thoracentesis
is a particular asset of US.. Examples are shown in figure 2, 3. Magnetic-resonance imaging (MRI)
is a highly refined, not generally available technique, which will rarely be required but does have
differential diagnostic merits in the analysis of critical borderline relationships i. e. distinguish‐
ing between inflammatory- infiltrative and malignant-destructive pleural processes via different
T-weighted sequences [37]. Very recently a role of PET-CT has also been described. PET-
imaging may indeed provide differently extensive focal and impressing laminar changes which
however remain indistinguishable from malignant lesions [38].
5.2. Immunologic tests
5.2.1. Tuberculin skin reaction
The tuberculin skin reaction is traditionally considered an indispensable tool in the diagnosis
of tuberculosis in general and likewise in tuberculous pleurisy although it is less reliable than
in pulmonary TB. The rate of false negative reactions to PPD has been given as high 30 % of
cases but even figures up to < 41 % have been reported [31, 32, 33], the variability possibly
reflecting non-standardised test doses. Still however there remains an amazing false negative
rate. There is no absolutely satisfying hypothesis to explain this paradoxon, let alone unequiv‐
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Figure 3. Ultrasound detection of multiple chambers in pleuritis exudativa tuberculosa
Figure 2. Ultrasound detection of inflammatory visceral membranes and consecutively trapped lung in pleuritis exu‐
dativa tuberculosa
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ocal experimental evidence. It appears a valid speculation to consider a local pooling of
sensitised T-lymphocytes at the site of infection responsible. Animal experiments and clinical
investigations have shown sequestration of PPD-sensitized lymphocytes to the pleural
compartment actually to occur in the early phase of infection leading to their systemic
depletion [39]. As a presumptive additional mechanism the presence of adhering suppressor
cells to blood lymphocytes has been demonstrated in PPD-anergic patients [39]. While the
explanatory evidence may remain scanty, it should be emphasised that in clinical practice the
phenomenon appears to be transitory and restricted to the early phase of tuberculous infection.
It might thus be associated with the pre-allergic phase of tuberculous infection, since conver‐
sion of skin reactivity has been subsequently observed within a 6-8 weeks delay [27]. As a
reverse conclusion in the framework of discussed hypotheses the observation of a delayed
PPD-conversion might be interpreted as a clue to primary infection to have occurred. Persisting
anergy would then point to other immune-modulating factors like advanced age, certain drug
interference or immune-compromising comorbidity.
5.2.2. Interferon-γ-release assays
In Europe commercially available Interferon-γ-release assays (IGRA) are the QuantiFERON-
TB-Gold-Test and the T-Spot-TB-Test. Both use the MTB-RD1-region antigen sequences CFP10
and ESAT 6 and measure the specific lymphocyte-induced quantitative IFN-γ-response or the
sensitized IFN-γ-producing lymphocyte response, respectively. There has been elaborated a
body of clinical data in practical use highlighting both the assets and pitfalls of the investiga‐
tion. In summary and in general there is distinct superiority to the PPD-skin-test with an overall
sensitivity of ~ 85 % and a high specificity well > 90 % [40]. The concordance of the PPD-test
and IFN-γ-release assays is in the order of 60-85 % [41]. However in the identification of active
clinical tuberculosis blood-based IFN-γ-release assays also have revealed a considerable rate
of false negative findings. In several studies including pulmonary a well as pleural tubercu‐
losis, sensitivity was limited to 60-64 % [42, 43, 44]. There have also been a number of incon‐
sistent and equivocal reports where the results obviously vary with different TB-prevalence
settings (i. e. pretest probability). In a number of studies the variability of sensitivity ranges
between 96 % in low prevalence settings down to 58 % in studies featuring high prevalence
areas, also specificity setbacks are reported [45]. Blood-based IGRA´s therefore seem to share
the limitations of PPD-testing. Since they cannot distinguish latent from active TB, in conclu‐
sion, the diagnostic value for identification of tuberculous pleurisy in high prevalence settings
is very low and has even only limited value in industrialized countries.
5.3. Pleural fluid analysis
5.3.1. Biochemical parameters
When there is enough effusion to allow safe puncture and TB is suspected, thoracentesis is a
mandatory diagnostic step. The effusion will be invariably and markedly exudative with a
(unless in tuberculous empyema) clear, straw- to amber-coloured appearance and a mean
protein content above 5.0 g/dl, in one series (n=83) it was 5.2 g/dl (range 3.5 – 7.0) [32]. Glucose
and pH-values have traditionally believed to be characteristically low in TB. It appears
however, that on the basis of more recent data, as also confirmed in the author´s own experi‐
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ence these values are not substantially different from exudates due to other aetiologies. SAHN
[46] found pH-values < 7.29 and glucose values < 30 mg/dl in only 20% of patients and this has
been confirmed by others [47]. Interestingly however, if low values actually occur, they appear
to correlate with the pleural bacillary load and are to some extent predictive of cultural results.
In one thoracoscopic study positive pleural fluid culture yield was 59 % when the glucose level
was < 50 mg/dl but only 25 % when the glucose values were > 50 mg/dl (p<0.005) [18]. Lactic
dehydrogenase (LDH) is a non-specific marker of pleural inflammation, which may be
excessively elevated in tuberculous pleurisy, although with a mean value of 423 IU/ml (range
43 – 1.575) as reported in a representative series again does not discriminate TB from para‐
pneumonic and not even from malignant effusion [32]. Adenosine deaminase (ADA) has been
a promising and much hailed semispecific biochemical parameter. ADA is an inflammatory
enzyme expressed predominantly by sensitized and activated T-lymphocytes. Isoenzymes
(ADA2) in addition reflect to some extent monocyte/macrophage activation. Thus increased
ADA-activity in general indicates various T cell/macrophage interactive inflammatory
processes like granulomatous disease but also empyema and collagen vascular disease. It
appears however particularly sensitive to TB. In a key study (n=129) in patients < 35 yrs a
receiver operating characteristics (ROC) –derived cut-off level of 47 U/ml allowed distinction
of tuberculous effusion from empyema, rheumatic and neoplastic disease with a 100 %
sensitivity and 87.5 specificity. When empyema was eliminated, specificity and the positive
predictive value even attained 100 % [48]. There are important limitations to the interpretation
of these results and their clinical relevance:
• the data reflect the afore mentioned age group only, in more heterogenous groups both
sensitivity and specificity have to be (down)-corrected to 95 % and 90 % respectively [22,
49, 50].
• the results strictly apply to high TB prevalence settings only and do not allow for different
pre-test prohabilities [3].
• also immune suppression like in AIDS endemic areas may interfere with inflammatory
ADA-release and invalidate diagnostic conclusions [3, 51].
Nevertheless, based on the most accepted cut-off level of 40 IU/l and provided its critical use
in areas of at least intermediate TB-prevalence ADA determination must be regarded as a true
diagnostic enrichment. An era of successful ADA-use has been recently summarized and
confirmed by a large size metaanalysis (63 studies, 5297 tuberculous and non-tuberculous
effusions) resulting in a sensitivity and specificity of 92 % and 90 % respectively [52].
5.3.2. Cytological analysis
Based on the immunological processes involved, a marked lymphocytosis is the predicted and
characteristic feature of TB-pleurisy along with significantly increased total white cell counts
as reflected in one representative study with a mean count of 2.309/mm3 (range 30 – 24.009
mm3) [32]. Usually 90 – 95 % of pleural fluid cells are T-lymphocytes, the remainder being B-
lymphocytes and (mostly) activated mesothelial cells. Only exceptionally (in ~ 5 %) lympho‐
cyte counts < 50 % may occur [27]. Thus when an 80 % lymphocyte reference line is chosen,
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pleuritis tuberculosa exudativa is by far the most frequent cause of pleural lymphocytosis [46].
Rarely, in particular in the early phase of inflammation fluid cytology may reveal neutrophil
leucocyte (PMN) predominance. Expansion of the eosinophil compartment would be an
extremely unusual finding. In the presence of significant numbers of eosinophils (> 5 %)
differential diagnoses should be considered.
5.3.3. Microbiological studies
The microbiological yield from diagnostic (low volume) thoracentesis as far the smear is
concerned is very low unless the whole effusion or large amounts are being centrifuged or the
patient has a tuberculous empyema [14, 29]. In HIV positive individuals, particularly in those
with CD4 cell counts < 200 x 106/l significantly higher yields are being reported amounting in
one study to 37 % vs. 0 % in non HIV-patients [53]. In a comprehensive study on microbiologic
smear findings in pleural fluid specimens in non-selected HIV negative out-patients, the
positive acid fast smear yield (n=232) again was actually zero [54]. Cultures should be obtained
both from the sputum and pleural fluid. The positive cultural yield from pleural fluid has been
given in collective reviews with 10 – 35 %, being ~ 25 % in the mean [14, 30]. In one of the largest
series (n=100] the sensitivity of pleural fluid culture was 28 % [18, 55]. The use of radiometric
or non-radiometric liquid culture systems (BACTEC, MB/BacT, MGIT) will markedly acceler‐
ate results and possibly lead to an enhanced yield (~ 50 %), when bedside instead of laboratory
inoculation is used [56]. The yield of sputum cultures in tuberculous effusion is expectedly
largely dependent on the extent and nature of pulmonary involvement and may mount up to
~ 50 %. In the non-expectorating patient the use of induced sputum is advised [57]. The positive
yield is also believed to be higher in HIV-infected patients [53, 57]. In the complete absence of
pulmonary lesions according to most sources the sensitivity will be no more than 4-7 % [30].
Only exceptionally a surprisingly high figure of 31 % for induced sputum has been reported
[57].
5.3.4. Immunological and molecular studies
Immunological studies of pleural fluid in TB-pleurisy focus on the measurement and analysis
of chemokins and interleukins that are characteristically associated with the tuberculous
immune response. TNFα and IFNγ revealed at a cut-off 140 pg/ml a sensitivity of 94 % and a
specificity of 85 % [58,60]. Similarly as for ADA the major confounders were bacterial empyema
and parapneumonic effusion respectively. Interestingly TNFα did not attain enough discrim‐
inatory power to separate TB from various inflammatory conditions and is no more considered
a valid option in the diagnosis of TB. More recent meta analysis-derived collective data from
22 studies resulted in an overall sensitivity of 89 % at a 97 % specificity [61]. Thus at present
IFNγ-determination in pleural fluid – contrasting to systemic IGRA-application – would
appear a useful diagnostic test with a sensitivity and discriminatory power comparable to that
of ADA-determination if one was to accept the significantly higher costs and disregard more
powerful diagnostic options as provided by subsequently discussed invasive biopsy techni‐
ques.
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Molecular mycobacterial identification methods employing a variety of nucleic acid amplifica‐
tion techniques (NAAT) have been applied in TB pleurisy with considerable enthusiasm and
expectations ever since their first application in TB in 1989 [62]. The techniques that have been
used include target amplification (polymerase chain reaction, PCR), strand displacement
amplification (SDA), transcription mediated amplification (TMA), probe/primer amplification
(ligand chain reaction, LCR) and Q-Beta replicase amplification mostly with the IS 6110, 16S
recombinant ribonucleic acid (rRNA) and 65 XD target sequence [63-66]. So far published data,
both biopsy- and pleural fluid-based have shown considerable variance of diagnostic yield,
which ranged from 20-81 % as to sensitivity with an expectedly high specificity in the order of
98-100 % (table 1). When analyzing the sources of this high variance, apart from technical
factors like contamination-related “carry over” or amplification inhibitors, the most important
determinant appeared to be the number of bacilli in the pleura fluid or specimen sample [31].
Although theoretically requiring the presence of merely one microorganism to trigger
amplification, similar to sputum anlysis, failed to detect pleural MTB in particular when the
pleurisy was paucibacillar, correlating with cultural negativity. In addition to fluid samples
numerous studies have evaluated the value of various nucleic acid extraction and amplifica‐
tions techniques in formalin-fixed and paraffin-embedded pleural tissue specimen [67-71].
With the use of commercial kits of both DNA amplicons (ligand chain MTB assay, LCxMTB
or AMPLICOR MTB) or RNA amplicons (amplified MTB direct test, AMTDT) according to the
latest currently available sources, the sensitivity of each single technique did not exceed 63.2
% albeit at an expected 100 % specificity [71]. The so far largest meta-analysis including 40
studies and featuring commercial as well as in-house (“home-brew”) tests, confirms a low and
heterogeneous sensitivity (in the mean 62 %) and high specificity of 98 % [72]. Thus there is
no convincing evidence, that generally and especially in the critical issue of paucibacillar
(cultural negative) pleurisy, NAATs perform substantially better in tissue than in effusion
specimens (table 1). Although in-house assays have been reported to be slightly superior [73],
there remain significant sensitivity set backs both in liquid- and tissue-derived specimen. In
summary NAATs may offer certain advantages like quick results within hours or added
specificity. They may also improve sensitivity in combined and parallel use with conventional
methods and multiple amplicors (diagnostic confirmation), but can certainly not replace or
obviate the need for conventional tools in the diagnosis of TB pleurisy.
5.3.5. Invasive bioptic and endoscopic studies
Bioptic techniques in the evaluation of tuberculous effusions incorporate closed blind or
imaging guided needle biopsy and medical (video)-thoracoscopy. Only exceptionally, if ever,
surgical  diagnostic  efforts  including  video-assisted  surgical  thoracoscopy (VATS)  would
appear appropriate. Invasive techniques are indicated when clinical investigation and pleural
fluid analysis provide only ambiguous or conflicting results and this is particularly true if
relevant differential diagnoses like malignancy need to be reliably excluded. Needle biopsy
may be considered a first step. There are no clear preferences as to the type of needle to be
used, although in the author´s opinion the Tru-Cut or Raja-system may be preferable to the
older  Abrams-  or  Ramel-needle  by  providing  a  larger  specimen along with  easier  han‐
dling. It is recommended, that at least six biopsies are obtained, since they will not regular‐
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ly contain a representative parietal pleural sample [74]. With this premise and the expected
yield of at least two valid samples closed needle biopsy should be diagnostic in tubercu‐
lous pleurisy in ~ 60 % of cases, when histology and tissue-, as well as fluid-culture are being
combined. In a major series (n=100 %) a 61 % positive yield was composed of 51 % biopsy
yield and 28 % positive fluid culture (figure 4) [18, 55]. Distinctly higher yields have also
been reported in the literature, leading in a collective review to an average sensitivity of 69
% (range 28-88 %) [75]. The difference and wide range is likely to be due to technical disparities
and inclusion of data originating from largely different prevalence areas. In one study from
a high prevalence area (South Africa) comprising 51 patients with undiagnosed pleurisy the
positive closed needle yield in tuberculous pleurisy (histology+AFB-stain+culture) was 79%,
when combined with pleural fluid ADA-determination and a lymphocyte/neutrophil ratio >
0.75 sensitivity increased to 93% at a specificity of 100% [76]. Thus with the parallel use of
less invasive parameters needle biopsy approaches the diagnostic potency of more inva‐
sive techniques and would appear the second best diagnostic option in areas with limited
medical logistics and resources.
Medical thoracoscopy as a “window to the pleural space” [77] is the gold standard procedure in the
evaluation of exudative pleural effusion, hence also pleural pleurisy. The current and future
role of thoracoscopy needs to be redefined for its diagnostic and interventional efficacy in the
light of its close historical affiliation with TB. In fact tuberculosis was already a major focus of
medical thoracoscopy or “pleuroscopy” as referred to and initiated by JACOBAEUS back in
Table 1. Role of Nucleic-Acid-Amplification-Techniques (NAAT) in the Diagnosis of Tuberculous Pleuritis
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1910 [78]. Anticipating modern minimally invasive surgical techniques, now all included
under the heading video-assisted thoracic surgery (VATS), his pioneering approach to thoraco‐
scopy was basically interventional with the intention to optimize pneumolysis and to break
strands for artificial pneumothorax induction in pulmonary TB (“Jacobaeus operation”).
However the ability to visualize major portions of the pleural surface, to intervene in the
presence of membranes, adhesions and septae with the option of numerous dedicated biopsies
also ensures optimum diagnostic results that are reflected in a yield of 94-99 % as confirmed
in decades of clinical experience [18, 77-81]. At thoracoscopy tuberculous pleurisy usually
appeals to the experienced investigator with characteristic and fairly diagnostic inflammatory
patterns.
• One may present with abundant fibrinous membranes, septae, loculations and diffuse
inflammatory thickening of the parietal and visceral pleura as the prevailing pattern. An
example of this endoscopic pattern is shown in figure 5.
• A second characteristic feature is a more or less intensive seeding of the pleural surface with
solid or caseous, sago-like nodules and only scanty fibrin deposits as shown in figure 6.
Although usually fairly small, major nodules as also shown in figure 6 may easily be
confused with malignant lesions.
• Tuberculous empyema as exemplified in figure 7 may be visually indistinguishable from non-
specific bacterial empyema unless calcifications, irreversible lung trapping or suspect
pulmonary lesions suggest a tuberculous origin.
Similarly to closed needle biopsy a sufficient number of biopsies – at least three- should be
obtained to warrant optimum and representative results. This may often require mechanical
debridement of membranes and septae to gain access to the inflamed pleura. When thoraco‐
Closed needle 
biopsy
Pleural fluid 
thoracentesis
Medical 
thoracoscopy
51 
61
28 99
100
According to Loddenkemer et al. [55]
Figure 4. Single and cumulated yield (%) of various microbiological and bioptical investigations in tuberculous pleurisy
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scopic results are combined with aforementioned techniques positive results may be aug‐
mented to virtually 100 % (fig. 2) [18].
Thoracoscopy also provides a number of additional advantages:
• With the reasonable diagnostic certainty of visual findings combined with an immedi‐
ate  histological  yield  of  >  90  %  it  allows  instant  implementation  of  antituberculous
chemotherapy
• The percentage of positive TB-cultures obtained from biopsies and fibrous membranes may
be twice as high (78 %) as from needle biopsies and pleural fluid combined (39 %) [77]. This
in turn provides superior opportunity for drug susceptibility testing.
• Complete removal and subsequent drainage of pleural fluid with pulmonary re-expansion
provides instant relief to the patients and warrants better healing and outcome options (see
section on therapy).
Male 48 years, pleuritis tuberculosa exsudativa
Figure 5. Typical thoracoscopic aspect of fibrin-type multi-loculated effusion including septae and chambers in tuber‐
culous pleurisy
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• In addition thoracoscopy may be easily expanded to an adjuvant therapeutic intervention
by breaking adhesions and debridement of membranes as also discussed in the section on
therapy.
In the overall assessment of biopsy techniques the experienced investigator will therefore
bypass closed needle biopsy and prefer thoracoscopy. Closed needle biopsy however will
remain the second best alternative if
• there is no logistic option for thoracoscopy or
• in the presence of clinical obstacles such as contraindications or mal-detachment of the lung
due to adhesions or advanced obliteration of the pleural space.
In summary, for the diagnosis of tuberculous pleurisy it appears and remains a well-founded
clinical policy to push for the recovery of biopsy specimens whenever possible and to combine
these with less invasive test results to ensure optimum management of the condition.
Male 24 years, pleuritis exsudativa tuberculosa
Figure 6. Typical thoracoscopic aspect of sago-type disseminated small and larger nodules both of the parietal and
visceral pleura giving rise to confusion with malignancy
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6. Therapy options
6.1. Systemic therapy
Basically systemic therapy of tuberculous pleurisy in the moderately ill patient neither differs
in intensity nor duration from antituberculous chemotherapy of pulmonary and other organ
tuberculosis in general. Current short term recommendations for non-complicated pulmonary
and extrapulmonary organ tuberculosis call for a quadruple drug therapy in the 2-month acute
phase in the combination of 5 mg/kg Isoniacid (INH), 10 mg/kg Rifampicin (RMP), 30-35 mg/
kg Pyrazinamid (PZA) and 20-25 mg/kg Ethambutol (EMB) or 15 mg/kg Streptomycin (SM),
where daily alternation of the SM and EMB component may be preferable [82]. In the second
4-month stabilizing phase a INH/RMP dual therapy is recommended. Until the 1990-years a
triple therapy in the initial phase for Tb was considered safe enough in view of a low incidence
of primary drug resistance. The quadruple therapy recommendation is therefore an amend‐
ment to a meanwhile globally changed drug susceptibility situation. Thus in an un-clarified
clinical setting the extent of drug resistance expectation will modify treatment strategies. The
Male patient, 48 yrs
Figure 7. Typical thoracoscopic aspect of tuberculous („specific“) empyema showing putrid parietal coverings includ‐
ing bioptic lesion and circumscript coin-like pleural thickening
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current policy in the case of tuberculous pleurisy therefore holds, that in lone and paucibacillar
pleurisy (without lung parenchymal lesions) after immediate quadruple therapy a down-
grading to a historical triple scheme is safe enough, provided full drug susceptibility is
warranted. In the presence of lung parenchymal involvement the full standard scheme would
however apply. The current average drug resistance probability is reflected in one major series
(n=78) with a rate of 6.4 %, being probably representative for Middle Europe [55].
The addition of an oral or parenteral steroid regimen to antituberculous drug therapy has been
discussed controversially. The rationale put forward for this approach focuses on
• the assumption of a shorter, attenuated clinical course in the severely ill patient,
• improved outcome by prevention of sequels in terms of pulmonary encasement and
fibrothorax.
Three valid clinical studies employing a randomized, double-blind controlled design may be
considered to have basically settled the issue [83, 84, 85]. These studies consistently showed,
that a tapering steroid therapy for 4 and up to 12 weeks starting with 0.5, 0.75 and 1.0 mg/kg/
day prednisone added to a standard antituberculous drug regimen, although mitigating and
shortening the clinical course to a moderate extent in two studies, did not alter any of the
outcome endpoints (clinical status, effusion resolution, pleural sequelae, lung volume and gas
exchange). In conclusion from these data, steroids would generally not appear indicated in
TB-pleurisy, a reasonable practice however would be a temporary use in the presence of a
severe febrile and consumptive clinical course. Their long term use for the prevention of fibrotic
sequels would appear obsolete.
6.2. Local therapy
Local therapy is an option, which is usually directly derived from a thoracoscopic approach
to the management of the condition. First of all it needs to be emphasized that the (possibly
complete) evacuation of pleural effusion is already an important topic treatment approach.
While this can basically be achieved by non-endoscopic techniques like simple thoracentesis
and small bore catheters as well, there is no doubt, that thoracoscopy will be disparately more
effective due to the ability of visual guided optimum positioning and the use of large bore
drains. In addition there is ample clinical evidence, that expert medical thoracoscopy can open
intrapleural loculations and chambers, completely evacuate sequestrated effusion compart‐
ments and also to some extent produce effective debridement of membranes. Although no
controlled study has so far proven the value of such efforts, from the view of the expert
endoscopist it would appear a straightforward and convincing approach. Together with the
early induction of antituberculous chemotherapy it might be responsible for the fact that in
our institution over more than two decades of experience none of the patients needed decor‐
tication subsequently.
Another more recently discussed approach in topical therapy would be, by a rationale
analogue to non-specific bacterial empyema, the use of fibrinolysis (streptokinase) which even
need not necessarily be linked to an endoscopic protocol. There is so far only scanty experience
[85]. However one fairly comprehensive study from Taiwan using a non-endoscopic pigtail
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catheter technique and comparing a loculated streptokinase group (n=22) with a loculated
normal saline irrigation group (n=22), reported significantly better outcome both in clinical
terms of imaging and functional criteria [86]. Additional future evidence provided, this would
seem an encouraging step towards further improvement in acute tuberculous pleurisy
management.
Surgery in the era of antituberculous chemotherapy is only exceptionally required in the
management of tuberculous involvement of the pleura. Remaining indications refer to rare
instances of previously mentioned tuberculous empyema and in particular its complications.
Specific issues in this context would be excessive membrane formation with trapped lung and
significant long term pulmonary encasement due to fibrothorax. Due to the scarcity of
pertinent cases and studies (at least in the western hemisphere) there are no generally accepted
surgical guidelines for the management of these conditions. Surgical decisions must be created
in an individual case-determined approach. A reasonable policy would appear to perform lone
or combined empyemectomy/pleurectomy, also termed early decortication in clinically severe
and functionally disabling conditions refractory to medical efforts. These indications may be
amenable to video-assisted thoracic surgery (VATS)-based interventions. Formal thoracotomy
would however be required if it comes to additional lung parenchymal resection or thoraco‐
plasty in rare complicated cases e.g. with persisting pyopneumothorax with or without
trapped lung due to a large, medically intractable broncho-pleural fistula.
A different issue is severe, chronically trapped lung due to fibrothorax. A reserved approach to
surgical strategies is generally advised because unexpected long term remission of inflammato‐
ry peels is sometimes impressing. Although decortication has been performed as early as 6 weeks
after the precipitating insult (empyema), the indication to late decortication is basically dis‐
cussed in the context of definitely and irreversibly trapped lung (fibrothorax) i.e. when at least
6 months have elapsed. With a focus on repair of lung function and prevention of chest deformity
most investigators agree that the indication requires a significant decrement of lung function
(TLC < 60% pred., reduction of perfusion > 50%) and level of deformity in the absence of significant
calcifications (pleuritis calcarea). Even then with extensive fibrotic fusion of both pleural sheaths
not only will surgery be fraught with considerable technical problems but also the certainty and
extent of functional improvement may not be predictable and warranted.
6.3. Sequels and prognosis
There are largely diverging data as to the prevalence of fibrothorax and permanent pleural
thickening as the most important sequel of pleural TB. In one source based on standard
radiographs in pleuritis exudative tuberculosa a percentage as high as 49 % has been given
[32]. With the strict definition of fibrothorax as a pleural membrane of at least 5 mm thickness
extending across major portions of the hemithorax and persisting > 8 weeks after initiation of
therapy a figure of ~ 5 % is a more likely and widely accepted rate of this complication. The
intensity of pleural inflammation expressed as interleukin levels and derangement of bio‐
chemical parameters is assumed to be to some extent predictive for this complication. In one
study residual pleural thickening was indeed significantly correlated with the magnitude of
the intitial change of inflammatory glucose-, pH- and TNF-α-levels [87].
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Caseous tubercus pleurisy and specific empyema respectively is in its natural course and in
prognostic terms an entirely different entity. These patients will invariably and typically
develop an extensive calcified fibrothorax (pleuritis calcarea) with or without concomitant
chest deformity. Also chronic non-specific lung disease (COPD) with or without bronchiecta‐
sis, late TB-exacerbations and internal or external fistulisation (specific empyema necessitans)
may develop. Anecdotical occurrence of non-HODGKIN lymphomas arising from long term
smouldering encasements has also been described.
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